The Institute for Clinical and Economic Review (ICER) is holding a review of current coverage policies of US insurers and pharmacy benefit managers. The institute plans to publish the first annual report on concordance between policies with fair access criteria by the mid-2021.
While the principles laid out in the new white paper “Cornerstones of ‘Fair’ Drug Coverage: Appropriate Cost-Sharing and Utilization Management Policies for Pharmaceuticals” will guide this review, ICER will be publishing a specific review protocol in November. This protocol will be informed by ongoing discussions with a cross-stakeholder Working Group that will provide helpful input. ICER will be solely responsible for the actual review of payer policies and the development of the final report. Read more here.